Belén Pérez-Dueñas

Belén Pérez-Dueñas

Auto-generated profile, based on publicly available information

Belén Pérez-Dueñas

Therapeutics and Innovations in Neuropediatrics and other paediatric rare diseases, Vall d'Hebron Institute of Research (VHIR) Instituto de Investigación Sanitaria Hospital Universitari Vall d'Hebron (IIS IR‐HUVH) Barcelona Spain

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2015 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
YCYanick J. Crow
Yanick J. Crow
DCDiana S. Chase
Diana S. Chase
JSJohanna Lowenstein Schmidt
Johanna Lowenstein Schmidt
MSMarcin Szynkiewicz
Marcin Szynkiewicz
GFGabriella M.A. Forte
Gabriella M.A. Forte
GRGillian I. Rice
Gillian I. Rice

11 February 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RMRaquel Montero
Raquel Montero
DYDèlia Yubero
Dèlia Yubero
JVJoan Villarroya
Joan Villarroya
DHDesiree Henares
Desiree Henares
CJCristina Jou
Cristina Jou
CJCecilia Jimenez-Mallebrera
Cecilia Jimenez-Mallebrera
We previously described increased levels of growth and differentiation factor 15 (GDF-15) in skeletal muscle and serum of patients with mitochondrial diseases. Here we evaluated GDF-15 as a biomarker for mitochondrial diseases affecting children and compared it to fibroblast-growth factor 21 (FGF-21). To investigate the mechanism of GDF-15 induction in these pathologies we measured its expression and secretion in response to mitochondrial dysfunction. We analysed 59 serum samples from 48 children with mitochondrial disease, 19 samples from children with other neuromuscular diseases and 33 samples from aged-matched healthy children. GDF-15 and FGF-21 circulating levels were determined by ELISA. Our results showed that in children with mitochondrial diseases GDF-15 levels were on average increased by 11-fold (mean 4046pg/ml, 1492 SEM) relative to healthy (350, 21) and myopathic (350, 32) controls. The area under the curve for the receiver-operating-characteristic curve for GDF-15 was 0.82 indicating that it has a good discriminatory power. The overall sensitivity and specificity of GDF-15 for a cut-off value of 550pg/mL was 67.8% (54.4%-79.4%) and 92.3% (81.5%-97.9%), respectively. We found that elevated levels of GDF-15 and or FGF-21 correctly identified a larger proportion of patients than elevated levels of GDF-15 or FGF-21 alone. GDF-15, as well as FGF-21, mRNA expression and protein secretion, were significantly induced after treatment of myotubes with oligomycin and that levels of expression of both factors significantly correlated. Our data indicate that GDF-15 is a valuable serum quantitative biomarker for the diagnosis of mitochondrial diseases in children and that measurement of both GDF-15 and FGF-21 improves the disease detection ability of either factor separately. Finally, we demonstrate for the first time that GDF-15 is produced by skeletal muscle cells in response to mitochondrial dysfunction and that its levels correlate in vitro with FGF-21 levels.

16 May 2019 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
AMAnna Marcé-Grau
Anna Marcé-Grau
LMLaura Martí‐Sánchez
Laura Martí‐Sánchez
HBHeidy Baide‐Mairena
Heidy Baide‐Mairena
JOJuan Dario Ortigoza‐Escobar
Juan Dario Ortigoza‐Escobar
BPBelén Pérez‐Dueñas
Belén Pérez‐Dueñas

8 April 2016 in Movement Disorders
Verified
Journal Article
Open access
PDF file
FCFlorence C.F. Chang
Florence C.F. Chang
AWAna Westenberger
Ana Westenberger
RDRussell C. Dale
Russell C. Dale
MSMartin Smith
Martin Smith
HPHardev S. Pall
Hardev S. Pall
VFVictor S.C. Fung
Victor S.C. Fung
Background: Adenylyl cyclase 5 (ADCY5) mutations is associated with heterogenous syndromes: familial dyskinesia and facial myokymia; paroxysmal chorea and dystonia; autosomal‐dominant chorea and dystonia; and benign hereditary chorea. We provide detailed clinical data on 7 patients from six new kindreds with mutations in the ADCY5 gene, in order to expand and define the phenotypic spectrum of ADCY5 mutations.Methods: In 5 of the 7 patients, followed over a period of 9 to 32 years, ADCY5 was sequenced by Sanger sequencing. The other 2 unrelated patients participated in studies for undiagnosed pediatric hyperkinetic movement disorders and underwent whole‐exome sequencing.Results: Five patients had the previously reported p.R418W ADCY5 mutation; we also identified two novel mutations at p.R418G and p.R418Q. All patients presented with motor milestone delay, infantile‐onset action‐induced generalized choreoathetosis, dystonia, or myoclonus, with episodic exacerbations during drowsiness being a characteristic feature. Axial hypotonia, impaired upward saccades, and intellectual disability were variable features. The p.R418G and p.R418Q mutation patients had a milder phenotype. Six of seven patients had mild functional gain with clonazepam or clobazam. One patient had bilateral globus pallidal DBS at the age of 33 with marked reduction in dyskinesia, which resulted in mild functional improvement.Conclusion: We further delineate the clinical features of ADCY5 gene mutations and illustrate its wide phenotypic expression. We describe mild improvement after treatment with clonazepam, clobazam, and bilateral pallidal DBS. ADCY5‐associated dyskinesia may be under‐recognized, and its diagnosis has important prognostic, genetic, and therapeutic implications. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society

1 December 2005 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
NLNilo Lambruschini
Nilo Lambruschini
BPBelén Pérez-Dueñas
Belén Pérez-Dueñas
MVMaria Antonia Vilaseca
Maria Antonia Vilaseca
AMAnna Mas
Anna Mas
RARafael Artuch
Rafael Artuch
JCJaume Campistol
Jaume Campistol

1 May 2016 in Mitochondrion
Verified
Journal Article
Closed access
JOJuan Darío Ortigoza-Escobar
Juan Darío Ortigoza-Escobar
AOAlfonso Oyarzábal
Alfonso Oyarzábal
RMRaquel Montero
Raquel Montero
RARafael Artuch
Rafael Artuch
CJCristina Jou
Cristina Jou
BPBelén Pérez-Dueñas
Belén Pérez-Dueñas